Contents lists available at ScienceDirect





Medical Mycology Case Reports

journal homepage: www.elsevier.com/locate/mmcr

Lomentospora prolificans vertebral osteomyelitis with spinal epidural abscess in an immunocompetent woman: Case report and literature review



Walaiporn Wangchinda^a, Piriyaporn Chongtrakool^b, Jantima Tanboon^c, Anupop Jitmuang^{a,*}

^a Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkoknoi, Bangkok 10700, Thailand

^b Department of Microbiology, Faculty of Medicine, Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkoknoi, Bangkok 10700, Thailand

^c Department of Pathology, Faculty of Medicine, Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkoknoi, Bangkok 10700, Thailand

ARTICLE INFO

Keywords: Lomentospora prolificans Vertebral osteomyelitis Spinal epidural abscess Immunocompetent patient

ABSTRACT

Lomentospora prolificans is a rare cause of vertebral osteomyelitis. We report a case of *L. prolificans* thoracic vertebral osteomyelitis with spinal epidural abscess in a patient without apparent immunodeficiency. Clinical manifestations and radiographic findings could not distinguish from other etiologic agents. Treatment is also challenging because *L. prolificans* is usually resistant to antifungal agents. The patient underwent surgical debridement and has been receiving a prolonged combination of antifungal therapy to prevent an infection relapse.

1. Introduction

Lomentospora prolificans (formerly known as Scedosporium prolificans) is filamentous fungus predominantly found in natural sources. L. prolificans can be transmitted to humans through inhalation of fungal particles, causing fungal colonization, localized pulmonary infection, or dissemination to distant organs [1]. The fungus can also be transmitted via direct inoculation following penetrating trauma or previous surgery rendering skin, soft tissue and osteoarticular infections. The disseminated infection is usually reported among patients with immunodeficiency conditions. In Thailand, L. prolificans infection had been reported in a patient who had prolonged neutropenia following chemotherapy for acute myeloid leukemia; the patient presented with a disseminated infection including pansinusitis, cutaneous hemorrhagic bulla, and multiple pulmonary nodules [2]. Vertebral osteomyelitis from L. prolificans is an uncommon infection and has been rarely reported. We report a case of L. prolificans vertebral osteomyelitis of the 8th (T8) and 9th (T9) thoracic spines with spinal epidural abscess in a patient without apparent immunodeficiency status.

(This work was presented in part at the 8th Trends in Medical Mycology (TIMM) Meeting, October 6–9, 2017 in Belgrade, Serbia.)

2. Case

A 57-year-old Thai woman who was previously healthy presented with chronic progressive mid-thoracic back pain for 3 months. The pain

caused the patient restricted to do daily activities. She was afebrile, but her weight decreased 8 kg in 3 months. She denied taking herbal medicines, illicit drugs, or corticosteroids. She had no previous surgery or back injury. She was hospitalized on 22 January 2017 (Day 0). Physical findings demonstrated tenderness over the mid-thoracic spines, hypertonia and hyperreflexia of the right lower extremities. Other examinations were unremarkable. Blood chemistries were in normal range. Anti-HIV testing was negative. Magnetic resonance imaging (MRI) of the thoracolumbar (TL) spines revealed destruction of the T8 and T9 vertebral bodies, pedicles and posterior elements, resulting T8 and T9 myelopathy, including spinal epidural abscess formation (Fig. 1). Three days after admission (Day +3), a T8 and T9 laminectomy found necrotic tissues and 3-mL pus located in the epidural space. The pathologic findings showed Splendore-Hoeppli phenomenon in pyogranulomatous reaction, and Gomori methenamine silver (GMS) staining highlighted groups of septate fungal hyphae (Fig. 2). Pus cultures grew black pigmented mold, later internal transcribed spacer (ITS) gene sequencing identified L. prolificans. Antifungal susceptibility testing showed MICs (μ g/mL) of amphotericin B of 8, 5flucytosine of > 64, fluconazole of > 256, itraconazole of > 16, voriconazole of 4, posaconazole of > 8, caspofungin of 8, micafungin of > 8 and anidulafungin of 4. Voriconazole 400 mg/day and terbinafine 500 mg/day were prescribed after ascertaining the fungal culture (Day + 12). An immunological testing panel including anti-interferongamma autoantibody, interferon-gamma receptor, interleukin 12 receptor, CD4 level, and CD8 level found no abnormality. A high

E-mail address: anupop.jit@mahidol.ac.th (A. Jitmuang).

https://doi.org/10.1016/j.mmcr.2018.03.008

Received 13 January 2018; Received in revised form 15 March 2018; Accepted 16 March 2018 Available online 19 March 2018

2211-7539/ © 2018 The Authors. Published by Elsevier B.V. on behalf of International Society for Human and Animal Mycology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).

^{*} Corresponding author.




Fig. 1. A: The MRI of TL spines demonstrated bony destruction of T8 and T9 vertebral bodies and posterior elements, causing myelopathy at T8–T9 levels with spinal epidural abscess formation. B: The follow-up MRI after the 6-month therapy demonstrated new and more progressive vertebral osteomyelitis at the T6, T7 and T10 spines, and circumferential soft tissue thickening with heterogeneous enhancement in epidural space, causing spinal canal stenosis.

resolution computed tomography (HRCT) of the chest did not identify contiguous pulmonary or mediastinal infectious foci causing the vertebral infection. The patient complied well with antifungal therapy, and voriconazole concentrations ranged from 1.5 to $2.0 \,\mu$ g/mL.

Following the 6-month antifungal therapy (Day +180), her back pain gradually resolved, but an MRI revealed new and more progressive vertebral osteomyelitis at the T6, T7 and T10 spines, and circumferential soft tissue thickening with heterogeneous enhancement in the epidural space, causing spinal canal stenosis (Fig. 1b). The dose of voriconazole was raised to 600 mg/day. The voriconazole concentrations ranged from 1.8 to $2.6 \,\mu$ g/mL following the incremental dose. Her back pain was in complete remission. The patient has continued the long-term combination antifungal therapy without serious complications.

3. Discussion

Vertebral osteomyelitis caused by fungal infection is rare, but the incidence has been increasing over the past several decades. *Aspergillus* spp. (38%) and *Candida* spp. (23%) are the two common etiologies of fungal vertebral osteomyelitis, for which recent surgery, organ transplant recipient, and malignancy are the risk factors [3]. The presented case had an unclear portal of infection, and had no previous injury or surgery of the spine. Inhalation of fungal spores can lead to pulmonary infection and occasionally causes metastatic infection to distant organs [1]. An HRCT of the chest was performed to evaluate if there was a pulmonary focus of infection causing direct invasion to the adjacent vertebra or dissemination to the distant vertebra. However, it revealed no radiographic findings suggestive of a pulmonary fungal infection.

Vertebral osteomyelitis and/or spinal epidural abscess caused by *L. prolificans* has been rarely reported in previous literature, as shown at Table 1 [4–6]. The previous case reports had risk factors or identified routes of infection, such as stem cell transplant, previous colonization, recent spine surgery, and previous spinal anesthesia [4–6]. All but one had back pain as a presenting manifestation. The duration of the presenting symptoms from all case reports tended to be chronic and slowly progressive from the onset. Fever was the presenting symptom in only

one patient, who developed spondylodiscitis of the affected sites following L5-S1 intervertebral disc herniation surgery [5]. The infectious foci were mostly located in the lower thoracic or lumbrosacral regions. However, the clinical manifestations and radiographic findings of *L. prolificans* vertebral osteomyelitis cannot be distinguished from other etiologic agents, such as bacteria, mycobacteria, and other fungi.

Diagnosis of this condition comprises a tissue biopsy sent for histopathological examinations and fungal cultures. From the presented case, the pathological section demonstrated pyogranulomatous inflammation with Splendore-Hoeppli reaction, which is not specific for fungal infection [7]. Tissue for fungal culture is required for diagnosis of invasive fungal infection. In our case, the fungal culture identified colonies of dematiaceous mold, which demonstrated single-celled conidia on elongated conidiophores under microscopic examination. The colony and microscopic structures cannot differentiate between Lomentospora spp. and Scedosporium spp. Thus, the ITS gene sequencing was used for species identification of the isolate in this case. Occasionally, species identification is crucial because virulence and antifungal susceptibility may vary among different species [8]. L. prolificans mostly demonstrates reduced in vitro antifungal susceptibility, and is associated with more invasive infections and higher mortality compared to S. apiospermum [1,9,10]. From Table 1, the isolates from the previous and the presented cases exhibited higher MICs to amphotericin B and itraconazole than voriconazole. A previous study demonstrated L. prolificans had moderate to high MICs to several antifungals agents, such as amphotericin B, conventional azoles, flucytosine, and echinocandins [1].

The optimal management of *L. prolificans* vertebral osteomyelitis remains inconclusive. Successful treatment generally requires adequate resection of infected foci and long-term antifungal therapy. Adequate surgical debridement is associated with favorable outcomes, particularly in localized or osteoarticular infections [11]. According to Table 1, all patients underwent surgical debridement combined with prolonged voriconazole therapy. Voriconazole has a relatively greater in vitro activity, and it can penetrate well into bone and the central nervous system [1]. Of 4 cases, 2 received a combination of antifungal agents. A combination of terbinafine and voriconazole or itraconazole showed a




Fig. 2. A: Fungal colony with Splendore-Hoeppli phenomenon in pyogranulomatous reaction (HE 20 \times magnification). B: High magnification revealed club shape eosinophilic material at the periphery of the fungal colony (HE 100 \times oil immersion). C: Septate fungal hyphae were highlighted in GMS stain (GMS 100 \times oil immersion).

synergistic effect against L. prolificans isolates [12], in which both agents inhibited an ergosterol synthesis of fungal cell wall at different sites of action [11]. Anecdotal data showed the combined voriconazole and terbinafine was used to treat a patient who had L. prolificans osteoarticular infection of the left ankle successfully [13]. However, the opitmal dosing regimen and duration of antifungal therapy are still unknown. The presented case has been receiving a prolonged combination of voriconazole and terbinafine to prevent a relapse of infection without serious adverse reactions.

In conclusion, L. prolificans is a rare cause of fungal vertebral osteomyelitis. Clinical manifestations and radiographic findings cannot distinguish from other etiologic agents. A high index of suspicion, pathological examination, and fungal culture are required for diagnosis. Antifungal susceptibility testing may assist in choosing the appropriate antifungal regimen. Adequate surgical removal of the infected focus and long-term antifungal therapy are required to achieve a successful outcome.

Acknowledgements

The authors would like to acknowledge neurosurgeons at Siriraj

Predisposing conditions V/sex MM, autologous HSCT, previous L. prolificans thinosinusitis	Presenting symptoms	Infectious foci					
53/F MM, autologous HSCT, previous L. prolificans rhinosinusitis	and weakness of		Infectious foci Radiographic findings	Pathological findings	Antifungal MICs (µg/mL)	Treatments	Outcomes
L. prolificans rhinosinusitis	it leg	L, S	L2, L3, L5 and S1 vertebral osteomyelitis with intervertebral discitis	Acute inflammatory	ABD 8	- Oral VORI, TBF	Partial recovery ^a
L. prolificans rhinosinusitis					ITRA > 16		
				reaction	VORI 2	- Laminectomy	
e spine surgery s	Fever and LBP	L, S	L5 and S1 vertebral osteomyelitis	n/a	ABD 16	- Oral VORI	Complete
months			with intervertebral discitis				recovery
Spain					ITRA 8	- Debridement and	
(2009) ⁴ 1 month	onth				VORI 8	arthrodesis	
3, 35/M Previous spinal epidural Progress	Progressive weakness of	Т	Spinal epidural abscess	Chronic inflammation and fungal	n/a	- IV and oral VORI	Relapse ^b
Brazil anesthesia 15 yrs lower li	lower limbs 6 yrs		at T9 and T10 levels	hyphae		- Laminectomy and	
(2009) ⁶						drainage	
The present 57/F – Mid tho	Mid thoracic back pain 3	Т	T8-T9 vertebral osteomyelitis and	Granulomatous inflammation,	ABD 8	- Oral VORI, TBF	Ongoing
case, months	iths		spinal epidural abscess	Splendore-Hoeppli reaction, and fungal ITRA > 16	ITRA > 16	- Laminectomy and	treatment
Thailand				hyphae	VORI 4	removal of	
(2017)					POSA > 8	abscess	

a, not available; POSA, posaconazole; S, sacrum; T, thoracic; TBF, terbinafine; VORI, voriconazole; yrs, years ^a Recovery of neurological deficits, but LBP and radiographic findings has been unchanged.

Relapse following discontinuation of antifungal therapy for 3 months.

Hospital for management of the patient; the staff of the Mycology Laboratory Unit, Department of Microbiology, for providing the microbiological data; and the staff of the Department of Pathology for providing the pathological data.

Conflict of interest

There are no conflicts of interest.

This study did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.

References

- K.J. Cortez, E. Roilides, F. Quiroz-Telles, J. Meletiadis, C. Antachopoulos, T. Knudsen, et al., Infections caused by *Scedosporium* spp, Clin. Microbiol. Rev. 21 (2008) 157–197.
- [2] P. Damronglerd, A. Phuphuakrat, P. Santanirand, S. Sungkanuparph, Disseminated Scedosporium prolificans infection in a patient with acute myeloid leukemia and prolonged febrile neutropenia, J. Infect. Dis. Antimicrob. Agents 31 (2014) 101–105
- [3] D. Ganesh, J. Gottlieb, S. Chan, O. Martinez, F. Eismont, Fungal infections of the spine, Spine (Phila. Pa 1976) 40 (2015) E719–E728, http://dx.doi.org/10.1097/ BRS.0000000000000903.
- [4] C. Garcia-Vidal, C. Cabellos, J. Ayats, F. Font, E. Ferran, P. Fernandez-Viladrich,

Fungal postoperative spondylodiscitis due to *Scedosporium prolificans*, Spine J. 9 (2009) e1–e7.

- [5] B.P. Howden, M.A. Slavin, A.P. Schwarer, A.M. Mijch, Successful control of disseminated *Scedosporium prolificans* infection with a combination of voriconazole and terbinafine, Eur. J. Clin. Microbiol. Infect. Dis. 22 (2003) 111–113.
- [6] F.J. Carod-Artal, L. Ferreira-Coral, J. Mauro-Couto, E. Gomes, M. de Agassiz-Vasques, Chronic spinal epidural abscess caused by *Scedosporium prolificans* in an immunocompetent patient, Spine (Phila. Pa 1976) 34 (2009) E330–E332, http://dx. doi.org/10.1097/BRS.0b013e31819964eb.
- [7] M.R. Hussein, Mucocutaneous Splendore-Hoeppli phenomenon, J. Cutan. Pathol. 35 (2008) 979–988.
- [8] H. Wang, Z. Wan, R. Li, Q. Lu, J. Yu, Molecular identification and susceptibility of clinically relevant *Scedosporium* spp. in China, Biomed. Res. Int. 2015 (2015) 109656, http://dx.doi.org/10.1155/2015/109656.
- [9] P. Troke, K. Aguirrebengoa, C. Arteaga, D. Ellis, C.H. Heath, I. Lutsar, et al., Global Scedosporium study Group.treatment of scedosporiosis with voriconazole: clinical experience with 107 patients, Antimicrob. Agents Chemother. 52 (2008) 1743–1750.
- [10] L. Cooley, D. Spelman, K. Thursky, M. Slavin, Infection with Scedosporium apiospermum and S. prolificans, Australia, Emerg. Infect. Dis. 13 (2007) 1170–1177.
- [11] A.A. Panackal, K.A. Marr, Scedosporium/Pseudallescheria infections, Semin. Respir. Crit. Care Med. 25 (2004) 171–187.
- [12] J. Meletiadis, J.W. Mouton, J.L. Rodriguez-Tudela, J.F. Meis, P.E. Verweij, In vitro interaction of terbinafine with itraconazole against clinical isolates of *Scedosporium prolificans*, Antimicrob. Agents Chemother. 44 (2000) 470–472.
- [13] I.B. Gosbell, V. Toumasatos, J. Yong, R.S. Kuo, D.H. Ellis, R.C. Perrie, Cure of orthopaedic infection with *Scedosporium prolificans*, using voriconazole plus terbinafine, without the need for radical surgery, Mycoses 46 (2003) 233–236.